Cargando…
Delayed diagnosis of Brugada syndrome in a patient with aborted sudden cardiac death and initial negative flecainide challenge
A negative flecainide challenge does not rule out Brugada syndrome even in the presence of nonfatal cardiac arrest as the first manifestation of the disease. This should prompt clinicians to ensure long‐term ECG follow‐up and consider repeating a drug test with another sodium channel blocker.
Autores principales: | Chauveau, Samuel, Le Vavasseur, Olivier, Chevalier, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715432/ https://www.ncbi.nlm.nih.gov/pubmed/29225848 http://dx.doi.org/10.1002/ccr3.1198 |
Ejemplares similares
-
Flecainide is a safe and effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle in pregnant women: a case series
por: Chauveau, Samuel, et al.
Publicado: (2019) -
Exercise Testing With Flecainide Demonstrates Provocable Brugada Syndrome
por: Safabakhsh, Sina, et al.
Publicado: (2021) -
Flecainide challenge test: Predictors of unmasking of type 1 Brugada ECG pattern among those with non-type 1 Brugada ECG pattern
por: Prasad, Srinivasa, et al.
Publicado: (2016) -
Wolff‐Parkinson‐White, Brugada phenocopy, and flecainide toxicity: All in one patient
por: Alhaj, Eyad K., et al.
Publicado: (2019) -
Brugada Syndrome as a Major Cause of Sudden Cardiac Death in Asians
por: Nakano, Yukiko, et al.
Publicado: (2022)